ObjectiveTo investigate the disease burden of non-alcoholic fatty liver disease （NAFLD） among young people in East Asian countries （including China， North Korea， Japan， Mongolia， and South Korea） in 1990—2023， and to provide a basis for formulating and adjusting the prevention and treatment strategies for NAFLD. MethodsRelated disease burden data of NAFLD among the young people in these five East Asian countries were collected from the Global Burden of Disease 2023 （GBD 2023） database， including incidence rate， prevalence rate， and disability-adjusted life years （DALY）， and the young people were divided into groups based on country， sex， and age. Estimated annual percentage change （EAPC） was used to comprehensively evaluate the changing trend of the disease burden of NAFLD among young people from 1990 to 2023， and the Autoregressive Integrated Moving Average model was used to predict the disease burden of NAFLD among the young people in China. ResultsIn 2023， the standardized incidence rates of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea were 926.57/100 000， 805.83/100 000， 412.66/100 000， 747.66/100 000， and 534.08/100 000， respectively； the standardized prevalence rates of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea were 16 817.94/100 000， 14 500.98/100 000， 8 534.40/100 000， 13 705.28/100 000， and 11 587.93/100 000， respectively； the standardized DALY rates of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea were 6.34/100 000， 10.18/100 000， 5.23/100 000， 47.93/100 000， and 6.76/100 000， respectively. From 1990 to 2023， there was a tendency of increase in the standardized incidence rate of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea， with an EAPC of 0.87%， 0.52%， 0.26%， 0.48%， and 0.87%， respectively； there was also a tendency of increase in the standardized prevalence rate of NAFLD among the young people in China， North Korea， Japan， Mongolia， and South Korea， with an EAPC of 0.99%， 0.49%， 0.24%， 0.59%， and 0.93%， respectively； conversely， there was a tendency of reduction in the standardized DALY rate of NAFLD among the young people in China， Japan， Mongolia， and South Korea， with an EAPC of -2.21%， -2.01%， -0.37%， and -4.62%， respectively， while the standardized DALY rate of NAFLD among the young people in North Korea remained relatively stable， with an EAPC of -0.01%. The subgroup analysis based on sex showed that there was a significant difference in the disease burden of NAFLD between the young people with different sexes in the five East Asian countries， and the subgroup analysis based on age showed that the incidence rate of NAFLD in young people decreased with the increase in age， while the prevalence rate and DALY rate of NAFLD increased with age. In addition， the standardized incidence rate and standardized prevalence rate of NAFLD among Chinese young people would further increase in the future， while there would be a reduction in standardized DALY rate in the future. ConclusionThere is a significant difference in the disease burden of NAFLD in young people across different countries， sexes， and age groups. In the future， targeted prevention and treatment measures should be developed based on the distribution characteristics of the disease burden of NAFLD， in order to effectively reduce the disease burden of NAFLD among young people.

Objective:To explore the effectiveness, safety, and cost among urinary follicle-stimulating hormone (u-FSH), recombinant FSH (r-FSH)α, and r-FSHβ in the early follicular phase prolonged protocol for patients under 35 years old with normal ovarian function.Methods:It was a retrospective cohort study. Patients under 35 years old with normal ovarian function who underwent early follicular phase prolonged protocol for ovulation stimulation and using in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) for fertilization in Reproductive Health Hospital of the Third Affiliated Hospital of Zhengzhou University from January 2018 to December 2023 were recruited, including the fresh and frozen-thawed embryo transfer (FET) cycles. Patients were divided into u-FSH group, r-FSHα group, and r-FSHβ group. A total of 1 048 ovarian stimulation cycles were included, with 150 cycles, 490 cycles and 408 cycles in the three groups respectively. A total of 710 FET cycles with fresh cycle cancellation were included, with 95 cycles, 320 cycles and 295 cycles in the three groups respectively. The baseline data, pregnancy outcomes, safety, and cost were compared among the three groups. The main observation indicators were cumulative pregnancy rate and cumulative live birth rate (CLBR). A binary logistic regression model was used to control confounding factors, and to analyze the relationship between three ovulation inducing medicine and CLBR. Results:The difference in the number of oocytes retrieved among the u-FSH group, r-FSHα group, and r-FSHβ group was statistically significant [13.0 (10.0, 16.0), 14.0 (11.0, 18.0), 15.0 (11.0, 19.0), respectively, P=0.012], and the difference in the number of 2PN embryos was statistically significant [9.0 (6.0, 12.0), 10.0 (7.0, 13.0), 10.0 (7.0, 13.0), respectively, P=0.046]. There were no statistically significant differences in the number of available embryos, available embryo rate, the number of high-quality embryos, high-quality embryo rate, available blastocyst formation rate, fresh cycle clinical pregnancy rate, live birth rate in fresh cycle, cumulative pregnancy rate of frozen embryos with fresh cycle cancellation, CLBR of frozen embryos with fresh cycle cancellation, cumulative clinical pregnancy rate, CLBR, moderate to severe ovarian hyperstimulation syndrome incidence, ectopic pregnancy rate, multiple pregnancy rate and neonatal malformation rate among the three groups (all P>0.05). In terms of economy, the u-FSH group had the lowest total gonadotropin cost for each patient, while the r-FSHα group had the highest. The differences among the three groups were statistically significant [u-FSH group 4 429.08 (3 198.78, 5 044.23) yuan, r-FSHα group 6 023.72 (5 433.75, 7 529.65) yuan, r-FSHβ group 5 480.00 (4 550.90, 6 437.86) yuan, P<0.001]. Binary logistic regression analysis was conducted, using u-FSH as a control. The CLBR of the r-FSHα group and r-FSHβ group showed no statistically significant difference compared with the u-FSH group (a OR=0.95, 95% CI: 0.57-1.58, P=0.838; a OR=0.89, 95% CI: 0.54-1.48, P=0.654). Conclusion:For patients under 35 years old with normal ovarian function undergoing long protocol ovarian stimulation, the effectiveness and safety of the three ovarian-stimulating medicine are similar, but u-FSH has economic advantages.

Objective:To study the clinical effect of omalizumab for asthmatic children,and to analyze its effect on immune re-sponse,inflammatory transmitters and airway remodeling.Methods:Eighty-two children with bronchial asthma in Nanyang Second People's Hospital from May 2018 to May 2022 were selected,and classified into Control group(n=36)and experimental group(n=46)according to the admission time.Control group received budesonide and formoterol fumarate powder for inhalation,based on this,experimental group received subcutaneous injections of omalizumab therapy.Palmaer method was applied to assess the clinical out-come of children.Forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and FEV1/FVC were measured using a spirometer.The percentage of Th1,Th2 and Treg cells were detected by flow cytometry.Levels of IL-4,IL-5,IFN-γ,TGF-β1,IL-10 and IL-35 were detected by ELISA.The lumen area(LA),wall area(WA)and percentage(WA%),and wall thickness(WT)of RB1(apical segment of the right upper lobe),RB10(posterobasal segment of the right lower lobe),LB1+2(apicoposterior seg-ment of the left upper lobe)and LB10(posterobasal segment of the left lower lobe)were obtained via CT scan,meantime,the quanti-tative assessment of the percentage of voxels below-950 hounsfield unit(HU)in inspiratory(IN-950),the volume at the end of deep inspiration(Vin)and the mean lung density(MLD)were also performed.Then comparison was conducted between two groups.Results:The clinical efficacy rate was 93.48%in experimental group,which was higher than 75.00%in control group,with statistical difference(P<0.05).No statistical difference was found in the lung function,immune response,inflammatory transmitters and airway remodeling between two groups before intervention(all P>0.05).After treatment,an increase in the lung function parameters FVC and FEV1,the immune response parameters Th1 cell ratio and Th1/Th2 levels,the expression level of the inflammatory transmitter IFN-γ,IL-10,IL-35,and the airway remodeling parameters LA normalized to body surface area(LA/BSA),WA/BSA and WT/√BSA,along with a decrease in Th2 and Treg cell percentage,IL-4,IL-5 and TGF-β1 expression and IN-950 were observed in experi-mental group compared with control group,with statistical difference(all P<0.05),while FEV1/FVC,WA%,Vin and MLDin no statis-tical difference between two groups(P>0.05).Conclusion:Omalizumab improves the clinical outcome of children with asthma by up-regulating the level of immune response,attenuating body inflammatory response and reducing airway remodeling caused by inflamma-tory stimuli,thus promoting the recovery of bronchial lumen of the children.

Objective:To explore the effectiveness, safety, and cost among urinary follicle-stimulating hormone (u-FSH), recombinant FSH (r-FSH)α, and r-FSHβ in the early follicular phase prolonged protocol for patients under 35 years old with normal ovarian function.Methods:It was a retrospective cohort study. Patients under 35 years old with normal ovarian function who underwent early follicular phase prolonged protocol for ovulation stimulation and using in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) for fertilization in Reproductive Health Hospital of the Third Affiliated Hospital of Zhengzhou University from January 2018 to December 2023 were recruited, including the fresh and frozen-thawed embryo transfer (FET) cycles. Patients were divided into u-FSH group, r-FSHα group, and r-FSHβ group. A total of 1 048 ovarian stimulation cycles were included, with 150 cycles, 490 cycles and 408 cycles in the three groups respectively. A total of 710 FET cycles with fresh cycle cancellation were included, with 95 cycles, 320 cycles and 295 cycles in the three groups respectively. The baseline data, pregnancy outcomes, safety, and cost were compared among the three groups. The main observation indicators were cumulative pregnancy rate and cumulative live birth rate (CLBR). A binary logistic regression model was used to control confounding factors, and to analyze the relationship between three ovulation inducing medicine and CLBR. Results:The difference in the number of oocytes retrieved among the u-FSH group, r-FSHα group, and r-FSHβ group was statistically significant [13.0 (10.0, 16.0), 14.0 (11.0, 18.0), 15.0 (11.0, 19.0), respectively, P=0.012], and the difference in the number of 2PN embryos was statistically significant [9.0 (6.0, 12.0), 10.0 (7.0, 13.0), 10.0 (7.0, 13.0), respectively, P=0.046]. There were no statistically significant differences in the number of available embryos, available embryo rate, the number of high-quality embryos, high-quality embryo rate, available blastocyst formation rate, fresh cycle clinical pregnancy rate, live birth rate in fresh cycle, cumulative pregnancy rate of frozen embryos with fresh cycle cancellation, CLBR of frozen embryos with fresh cycle cancellation, cumulative clinical pregnancy rate, CLBR, moderate to severe ovarian hyperstimulation syndrome incidence, ectopic pregnancy rate, multiple pregnancy rate and neonatal malformation rate among the three groups (all P>0.05). In terms of economy, the u-FSH group had the lowest total gonadotropin cost for each patient, while the r-FSHα group had the highest. The differences among the three groups were statistically significant [u-FSH group 4 429.08 (3 198.78, 5 044.23) yuan, r-FSHα group 6 023.72 (5 433.75, 7 529.65) yuan, r-FSHβ group 5 480.00 (4 550.90, 6 437.86) yuan, P<0.001]. Binary logistic regression analysis was conducted, using u-FSH as a control. The CLBR of the r-FSHα group and r-FSHβ group showed no statistically significant difference compared with the u-FSH group (a OR=0.95, 95% CI: 0.57-1.58, P=0.838; a OR=0.89, 95% CI: 0.54-1.48, P=0.654). Conclusion:For patients under 35 years old with normal ovarian function undergoing long protocol ovarian stimulation, the effectiveness and safety of the three ovarian-stimulating medicine are similar, but u-FSH has economic advantages.

Our acupuncture-moxibustion(Acu-Moxi)field has entered an era of digital and intelligent transformation,yet systematic and in-depth development remains limited.This article aims to provide an overview and reflection on the digital and intelligent progress of Acu-Moxi in China,offering systematic insights for the comprehensive development of this field.Through a retrieval from CNKI,VIP,and Wanfang databases,along with a discussion of relevant policies,case studies,achievements,and updates,the study evaluated the current advancements in the digitization and intelligence of Acu-Moxi,also discussing the current advantages and challenges.Findings revealed an overall upward trend in publications related to digital-intelligent technologies in Acu-Moxi,key forms including robotics,acupuncture point digitization,smart acupuncture devices,and clinical decision-making models,highlighting the empowering potential of digital intelligence across the discipline.Recently,publications of the Acu-Moxi digitization has decreased sharply,and the number of Acu-Moxi research about digital and intelligent transformation has increased.In conclusion,the field has undergone a transition from comprehensive digital accumulation to increasing intelligence,moving toward integrated digital-intelligent development.However,the internal development of digital and intelligent Acu-Moxi remains uneven.To achieve a harmonious intelligent Acu-Moxi ecosystem,it is crucial to leverage opportunities of discipline and times for systematic and balanced improvement.

Objective:To analyze and discuss the current status, hotspots and development dynamics of self-management in chronic heart failure (CHF) patients at home and abroad based on China National Knowledge Infrastructure and Web of Science databases.Methods:Literature on self-management of CHF patients was searched in China National Knowledge Infrastructure and Web of Science. The search period was from January 1, 2014 to May 31, 2024. Keyword cluster analysis was performed using Cite Space 6.3.R1 software.Results:A total of 411 articles in Chinese and 878 articles in English were included. In the past ten years, the annual publication volume of English literature was generally even, and the distribution trend of annual publication volume of Chinese literature showed an upward and then a downward trend. The hotspots of self-management of CHF patients in the Chinese literature mainly focused on health education, self-efficacy, and disease prognosis, and the hotspots of self-management of CHF patients in the English literature mainly focused on quality of life, disease management, and self-care.Conclusions:Analyzing the current status, hotspots and developmental dynamics of self-management in CHF patients can provide a reference for how to effectively promote self-management in CHF patients and conduct related research in the future.

Our acupuncture-moxibustion(Acu-Moxi)field has entered an era of digital and intelligent transformation,yet systematic and in-depth development remains limited.This article aims to provide an overview and reflection on the digital and intelligent progress of Acu-Moxi in China,offering systematic insights for the comprehensive development of this field.Through a retrieval from CNKI,VIP,and Wanfang databases,along with a discussion of relevant policies,case studies,achievements,and updates,the study evaluated the current advancements in the digitization and intelligence of Acu-Moxi,also discussing the current advantages and challenges.Findings revealed an overall upward trend in publications related to digital-intelligent technologies in Acu-Moxi,key forms including robotics,acupuncture point digitization,smart acupuncture devices,and clinical decision-making models,highlighting the empowering potential of digital intelligence across the discipline.Recently,publications of the Acu-Moxi digitization has decreased sharply,and the number of Acu-Moxi research about digital and intelligent transformation has increased.In conclusion,the field has undergone a transition from comprehensive digital accumulation to increasing intelligence,moving toward integrated digital-intelligent development.However,the internal development of digital and intelligent Acu-Moxi remains uneven.To achieve a harmonious intelligent Acu-Moxi ecosystem,it is crucial to leverage opportunities of discipline and times for systematic and balanced improvement.

Objective:To analyze and discuss the current status, hotspots and development dynamics of self-management in chronic heart failure (CHF) patients at home and abroad based on China National Knowledge Infrastructure and Web of Science databases.Methods:Literature on self-management of CHF patients was searched in China National Knowledge Infrastructure and Web of Science. The search period was from January 1, 2014 to May 31, 2024. Keyword cluster analysis was performed using Cite Space 6.3.R1 software.Results:A total of 411 articles in Chinese and 878 articles in English were included. In the past ten years, the annual publication volume of English literature was generally even, and the distribution trend of annual publication volume of Chinese literature showed an upward and then a downward trend. The hotspots of self-management of CHF patients in the Chinese literature mainly focused on health education, self-efficacy, and disease prognosis, and the hotspots of self-management of CHF patients in the English literature mainly focused on quality of life, disease management, and self-care.Conclusions:Analyzing the current status, hotspots and developmental dynamics of self-management in CHF patients can provide a reference for how to effectively promote self-management in CHF patients and conduct related research in the future.

Objective:To study the clinical effect of omalizumab for asthmatic children,and to analyze its effect on immune re-sponse,inflammatory transmitters and airway remodeling.Methods:Eighty-two children with bronchial asthma in Nanyang Second People's Hospital from May 2018 to May 2022 were selected,and classified into Control group(n=36)and experimental group(n=46)according to the admission time.Control group received budesonide and formoterol fumarate powder for inhalation,based on this,experimental group received subcutaneous injections of omalizumab therapy.Palmaer method was applied to assess the clinical out-come of children.Forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and FEV1/FVC were measured using a spirometer.The percentage of Th1,Th2 and Treg cells were detected by flow cytometry.Levels of IL-4,IL-5,IFN-γ,TGF-β1,IL-10 and IL-35 were detected by ELISA.The lumen area(LA),wall area(WA)and percentage(WA%),and wall thickness(WT)of RB1(apical segment of the right upper lobe),RB10(posterobasal segment of the right lower lobe),LB1+2(apicoposterior seg-ment of the left upper lobe)and LB10(posterobasal segment of the left lower lobe)were obtained via CT scan,meantime,the quanti-tative assessment of the percentage of voxels below-950 hounsfield unit(HU)in inspiratory(IN-950),the volume at the end of deep inspiration(Vin)and the mean lung density(MLD)were also performed.Then comparison was conducted between two groups.Results:The clinical efficacy rate was 93.48%in experimental group,which was higher than 75.00%in control group,with statistical difference(P<0.05).No statistical difference was found in the lung function,immune response,inflammatory transmitters and airway remodeling between two groups before intervention(all P>0.05).After treatment,an increase in the lung function parameters FVC and FEV1,the immune response parameters Th1 cell ratio and Th1/Th2 levels,the expression level of the inflammatory transmitter IFN-γ,IL-10,IL-35,and the airway remodeling parameters LA normalized to body surface area(LA/BSA),WA/BSA and WT/√BSA,along with a decrease in Th2 and Treg cell percentage,IL-4,IL-5 and TGF-β1 expression and IN-950 were observed in experi-mental group compared with control group,with statistical difference(all P<0.05),while FEV1/FVC,WA%,Vin and MLDin no statis-tical difference between two groups(P>0.05).Conclusion:Omalizumab improves the clinical outcome of children with asthma by up-regulating the level of immune response,attenuating body inflammatory response and reducing airway remodeling caused by inflamma-tory stimuli,thus promoting the recovery of bronchial lumen of the children.